At a glance

ClinicalIndex Comparison Record

Phase 2Unknown· 32 target

Drug / intervention

Pyrotinib +1 moredrug

Likely dose

Pyrotinib 400mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03923179

NCT03923179Phase 2Unknown

The Efficacy and Safety of Pyrotinib Combined With Etoposide in HER2-positive Advanced Breast Cancer

Chinese Academy of Medical Sciences·interventional·Posted Apr 22, 2019·Updated Apr 22, 2019

In Brief

A Phase 2 clinical trial evaluating Pyrotinib and Etoposide for Breast Cancer. Targeting 32 participants across 1 site.

The purpose of this study is to assess the efficacy and safety of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesChina

Collaborators--

Phase 2UnknownOverdue

2020202120222023202420252026

Enrollment StartApr 2019

First PostedApr 2019

Primary CompletionApr 2021

Study CompletionDec 2021

TodayJul 2026

First PostedApr 22, 2019

Enrollment StartApr 19, 2019

Primary CompletionApr 1, 2021

Study CompletionDec 31, 2021

TodayJul 1, 2026

Enrollment to primary: 1.9 yearsPosted 7.2 years ago

Pyrotinibdrug

Pyrotinib, 400mg qd

Etoposidedrug

Etoposide, 50mg，qd,d1-21,Q4W